Hengyu Medical Secures Tens of Millions in Funding Within Three Months for Second Time

Nov 05, 2023 08:07 CST Updated 08:07

Horimed

OCT Imaging Equipment R&D and Manufacturer

▎WuXi AppTec Content Team Report

News on November 3: Horimed announced the completion of a multi-million yuan financing round, led byBeiyang Begonia FundExclusive investment. According toHorimed News Release,This is the company's second financing completed within three months after receiving tens of millions of yuan in investment from Jinhuitong Fund earlier this year, with Haoyue Capital serving as the exclusive financial advisor once again. This round of financing will support R&D, production, and registration, with a particular focus on accelerating the commercial promotion of already listed products.

Horimed, established in 2016, focuses on the independent research, production, and sales of intravascular ultrasound (IVUS) equipment and catheters, optical coherence tomography (OCT) equipment and catheters, dual-catheter systems integrated with IVUS/OCT, non-invasive fractional flow reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology that combines OCT with near-infrared spectroscopy (NIRS), and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate based on foundational technologies, aiming to provide an integrated pan-vascular solution based on imaging products for medical professionals and patients.

Founder of HorimedMr. Liu ZhiyongStated that in the field of precise diagnosis and treatment of vascular intervention,HorimedA Long Road Ahead. We are very grateful for the consistent support from both new and existing shareholders, and also thank Haoyue Capital, our financing partner for this round. With the support of capital, we believe that in the future, the company will become an innovative company in intelligent diagnosis and treatment within vascular interventional endoluminal procedures, relying on its solid and innovative technology and products.

Founder of HorimedDr. Zhaoshi YongStated that, as a part of the precise diagnosis and treatment in vascular intervention, the company will focus on technology and products in the future, and also concentrate on assisting clinical practice to carry out systematic training in precise diagnosis and treatment in vascular intervention. Hoping to grow together with the majority of vascular intervention doctors, so that more and more doctors can understand, master, and are committed to promoting precise diagnosis and treatment in vascular intervention, ultimately benefiting more patients.

Initiating Partner of Beiyang海棠 FundMr. Wang RendaThe development of intravascular imaging has greatly promoted the popularization of precise PCI surgery.Among them, IVUS and OCT can significantly improve the accuracy of PCI procedures, and are greatly helpful for patient prognosis and reducing the incidence of postoperative adverse events.IVUS and OCT equipment and catheters are typical cross-disciplinary technologies integrating acoustics, optics, electronics, and imaging. Haitang Fund will continue to support the development of Horimed and the advancement of precision vascular intervention.

Mr. Yang Zhenjun, Managing Partner of Haoyue Capital, stated that comprehensive and precise diagnosis and treatment are the trends in medical development. Intravascular imaging is a powerful technique for achieving accurate diagnosis in the field of vascular intervention and has been recommended by clinical guidelines and widely recognized in high-end medical markets globally. Haoyue Capital continues to be optimistic.Horimed`, looking forward to more high-quality products being launched soon to benefit a large number of patients.`

References:

[1] Horimed Secures Additional Tens of Millions in Financing, Accelerating the Development and Commercialization of Endovascular Diagnostic and Therapeutic Products; HaoYue Capital Continues as Exclusive Financial Advisor | HaoYue.Deal. Retrieved Nov 3， 2023. From https://mp.weixin.qq.com/s/Kr5HjxJb4n90IbMhJAqj8w

This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media circles. For authorization to repost, please contact us via a message on the "MedView" WeChat Official Account. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.